Blog

Introduction to TNFRSF9 and Its Role in Immune ActivationTNFRSF9, also known as 4-1BB or CD137, is a co-stimulatory receptor expressed on the surface of T cells, natural killer (NK) cells, and dendritic cells. It belongs to the tumor necrosis factor receptor superfamily (TNFRSF), which plays critical roles in regulating immune responses. Activation of TNFRSF9 boosts the activity and survival of T cells and NK cells, making it a powerful target in cancer immunotherapy where enhanced anti-tumor immunity is essential for effective treatment.When TNFRSF9 binds to its ligand, 4-1BBL, expressed on antigen-presenting cells (APCs), it delivers a robust co-stimulatory signal that promote …

Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibitors showing success across various cancers by restoring T cell function and enhancing immune responses. PD-1, a receptor on T cells, interacts with its ligand PD-L1, which is commonly expressed on tumor cells and tumor-associated immune cells. This binding suppresses T cell activity, allowing tumors to evade immune destruction. However, PD-L1 is not the only ligand for PD-1—PD-L2 also binds to PD-1 and can significantly contribute to immune evasion in certain tumors.While most current therapies …

Introduction to CD86 and Its Role in Immune Activation CD86 is a crucial co-stimulatory molecule that plays an essential role in T cell activation, driving the immune system’s ability to recognize and destroy infected or cancerous cells. Expressed primarily on antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells, CD86 binds to receptors on T cells to regulate their activity. CD86 interacts with CD28 to provide a critical co-stimulatory signal necessary for full T cell activation, promoting proliferation, cytokine production, and effector functions in immune responses.In the context of cancer immunotherapy, harnessing CD86's co-stimulatory functi …

Introduction to CD80 and Its Role in Immune Activation CD80 is a critical immune checkpoint molecule that plays an essential role in T cell activation through co-stimulatory pathways. Expressed primarily on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages, CD80 interacts with receptors on T cells to regulate immune responses. Specifically, CD80 engages CD28 to provide a crucial co-stimulatory signal necessary for full T cell activation, proliferation, and differentiation. This co-stimulation amplifies the immune system's ability to recognize and attack pathogens, as well as cancer cells.In addition to its role in immune activation, CD80 can …

Introduction to TLR4 and Cancer Toll-like receptor 4 (TLR4) is a key component of the innate immune system, primarily responsible for detecting infections and initiating inflammatory responses. This receptor recognizes pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharides (LPS) from bacteria, and damage-associated molecular patterns (DAMPs) from injured or stressed cells. Once activated, TLR4 triggers the release of pro-inflammatory cytokines, which are crucial for defending the body against infections.However, the role of TLR4 in cancer is more complex. While TLR4-mediated inflammation is essential for immune protection, chronic inflammation driven by …

Introduction to CD73 and Tumor Immunosuppression CD73, also known as ecto-5'-nucleotidase, is an enzyme found on the surface of various cells, including tumor cells and immune cells. It plays a central role in producing adenosine, a molecule with potent immunosuppressive effects, particularly in the tumor microenvironment. By breaking down extracellular ATP (a danger signal) into adenosine, CD73 contributes to creating an environment that dampens immune responses, allowing tumors to evade immune surveillance and grow unchecked.The adenosine pathway has emerged as a critical target in cancer immunotherapy, as elevated adenosine levels within tumors lead to the suppression of …

Introduction to CD39 and Cancer Immunosuppression CD39 is an ectonucleotidase enzyme that plays a crucial role in generating adenosine, a powerful immunosuppressive molecule within the tumor microenvironment. By converting extracellular ATP (a danger signal that activates the immune system) into AMP, CD39 initiates the adenosine production pathway, which is completed by CD73. Adenosine, in turn, suppresses immune cell activity, particularly that of T cells, natural killer (NK) cells, and dendritic cells, thus protecting tumor cells from immune destruction.Targeting CD39 with therapies like BU69, a monoclonal antibody that inhibits CD39 activity, is a promising strategy to r …

Introduction to SLAMF7 in Cancer Immunotherapy SLAMF7, also known as Signaling Lymphocytic Activation Molecule F7, is a surface receptor found on natural killer (NK) cells, T cells, plasma cells, and certain immune-regulatory cells. This receptor plays a crucial role in modulating immune responses, particularly by enhancing the cytotoxic activity of NK cells, which are a critical part of the body’s first line of defense against tumors. The SLAMF7 receptor, also referred to as CD319, has garnered significant attention as a target for cancer immunotherapy due to its ability to activate NK cells and facilitate tumor destruction.In cancers such as multiple myeloma and solid tum …

Introduction to BTLA in Immune Regulation B and T lymphocyte attenuator (BTLA) is an immune checkpoint molecule that plays a critical role in regulating immune responses by suppressing T cell activity. Structurally similar to other inhibitory receptors like CTLA-4 and PD-1, BTLA functions as a negative regulator of immune activation, maintaining immune tolerance and preventing excessive inflammation. While this is essential for avoiding autoimmune diseases, it can also be exploited by tumors to escape immune surveillance. BTLA's role in immune regulation has made it a promising target for cancer immunotherapy, where blocking its inhibitory effects can restore T cell activit …

Introduction to CD122 in Immunotherapy CD122, also known as the interleukin-2 receptor beta chain (IL-2Rβ), is a critical component of the immune system's response to pathogens and malignancies. Its primary function is to mediate signaling through the IL-2 and IL-15 cytokine pathways, which are essential for T cell proliferation, survival, and differentiation. These T cells, particularly CD8+ T cells and natural killer (NK) cells, play a central role in the body’s immune defense against cancer and infections.In recent years, immunotherapy has become a transformative approach in cancer treatment. The ability to harness and modify the body's own immune system to fight tumors …

In recent years, cancer immunotherapy has become a powerful tool for treating various malignancies. One promising approach involves targeting the tumor microenvironment, particularly regulatory T cells (Tregs), which play a key role in suppressing the immune response against tumors. TNFR2 (Tumor Necrosis Factor Receptor 2) is highly expressed on Tregs within the tumor, making it an attractive target for immunotherapy. Antibodies such as https://www.assaygenie.com/tnfr2-taming-regulatory-t-cells-to-enhance-anti-tumor-immunity/, which block TNFR2, have the potential to enhance anti-tumor immunity by reducing the suppressive function of Tregs and promoting a more robust immune resp …

Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activation and immune memory. CD27 stimulation can enhance the immune system’s ability to detect and destroy cancer cells, making it an attractive target for immunotherapy. Antibodies such as AT124-5 are being developed to activate CD27, offering new hope for strengthening the immune response against cancer. What is CD27? CD27 is a member of the TNF receptor superfamily, expressed primarily on T cells and B cells. Its primary function is to enhance T-cell activation, support the formation of …

The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoints, which play a significant role in immune suppression within the tumor microenvironment. A relatively new target of interest is B7-H4, a member of the B7 family of immune-regulatory proteins. Emerging research indicates that blocking B7-H4 with antibodies such as MIH43 may offer promising therapeutic benefits in various cancers. This article explores the role of B7-H4, its biological functions, and how anti-B7-H4 therapies may improve cancer treatment outcomes.Assay Genie · B7 - H4 A New Fron …

Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this growing field is LILT (Leukocyte Immunoglobulin-Like Transcript), an immune checkpoint molecule that plays a crucial role in regulating immune responses. Blocking LILT with antibodies like 3G4 offers a promising strategy to restore immune surveillance and improve the effectiveness of cancer therapies.Assay Genie · LILT-A Novel Immune Checkpoint For Cancer TherapyWhat is LILT?Leukocyte Immunoglobulin-Like Transcript (LILT) is a family of receptors expressed predominantly on immune cells, particular …

Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell Co-Stimulator (ICOS), a molecule that enhances T-cell activation and function. Anti-ICOS antibodies, such as C398.4A, are being explored to amplify the immune response, making them a promising addition to cancer therapy strategies. Assay Genie · ICOS Stimulating The Immune System For Superior Cancer TherapyWhat is ICOS? Inducible T-cell Co-Stimulator (ICOS) is a member of the CD28 family of co-stimulatory receptors, which are critical for T-cell activation and survival. ICOS is expres …

PVR (Poliovirus receptor), also known as CD155, is a molecule that plays a dual role in regulating the immune response within the tumor microenvironment. While initially discovered as a receptor for poliovirus, PVR is now recognized for its involvement in modulating immune cell interactions, particularly in cancer. Its expression on tumor cells can both activate and suppress the immune system, making it an intriguing target for cancer immunotherapy. Antibodies such as Anti-PVR (e.g., D172) are being explored as potential therapeutic agents to restore immune function and improve tumor clearance. Assay Genie · PVR Balancing Immune Activation And Suppression In CancerPVR: An O …

The CD28 molecule plays a crucial role in amplifying T cell activation, which is critical for mounting effective immune responses against tumors. By engaging with co-stimulatory molecules, CD28 enhances T cell proliferation, survival, and cytokine production, making it an important target in cancer immunotherapy. In particular, Anti-CD28 antibodies, such as 37.51, are being explored to boost the immune system’s ability to fight cancer, offering a promising avenue for improved tumor clearance.Assay Genie · CD28: Amplifying T Cell Responses For Better Tumor ClearanceCD28 Overview: A Key Co-Stimulatory MoleculeCD28 is a co-stimulatory receptor expressed on T cells, essential for fu …

One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping tumors avoid immune attack. CD47, known as the “don’t eat me” signal, interacts with immune cells to prevent their destruction by the body’s defense systems. However, novel therapies targeting CD47, such as anti-CD47 antibodies like MIAP301, are showing promising results in reversing this evasion strategy by activating macrophages and enhancing the body's ability to eliminate tumor cells.Assay Genie · CD47 Overcoming Tumor Evasion Through Macrophage ActivationWhat is CD47?CD7 is a transmembrane …

Immunotherapy has become a central pillar in the fight against cancer, with a focus on enhancing the body’s natural defenses. Among the molecules at the forefront of immunotherapeutic research is 4-1BB (CD137), a co-stimulatory receptor that plays a key role in amplifying immune cell responses. Agonists like 1D8 target 4-1BB, unleashing potent anti-tumor immunity. This article delves into the function of 4-1BB, how agonists enhance immune responses, and their potential in https://www.assaygenie.com/blog/targetting-immune-checkpoints-as-cancer-therapyAssay Genie · 4 - 1BB Energizing Immune Cells To Overcome Tumor ResistanceWhat is 4-1BB (CD137)?4-1BB, also known as CD137, is a co …

Cancer immunotherapy has revolutionized treatment options, offering strategies to harness the immune system to target and destroy tumors. One emerging area of interest is the use of OX40 agonists, like OX86, which play a crucial role in amplifying the immune response against cancer cells. OX40 agonists show promise in several cancer models, potentially improving the efficacy of existing immunotherapies. This article will explore the mechanism of OX40, the role of OX40 agonists in cancer treatment, and ongoing clinical developments. Understanding OX40 and Its Role in Immunity OX40, also known as CD134, is a costimulatory receptor that belongs to the tumor necrosis facto …

Immune evasion is one of the hallmarks of cancer, where tumor cells employ various strategies to suppress immune responses and prevent destruction by the body’s defense systems. CD200, a transmembrane protein, has emerged as a key player in mediating immune suppression in the tumor microenvironment. Targeting CD200 with therapies like OX90 is a promising approach to disrupt this immune evasion, allowing the immune system to mount a more effective attack against cancer cells. This article delves into the role of CD200 in tumors, the therapeutic potential of CD200-targeting agents, and the ongoing research surrounding this pathway. Assay Genie · Targeting CD200 Unlocking Immu …

Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα-CD47 axis, which prevents macrophages and other phagocytic cells from attacking tumor cells. SIRPα inhibitors, such as P84, are emerging as novel immunotherapies that block this protective signal, allowing the immune system to recognize and engulf cancer cells. This article explores the role of SIRPα inhibition in enhancing phagocytosis, promoting anti-tumor immunity, and the therapeutic potential of anti-SIRPα agents like P84 in cancer treatment. Assay Genie · SIRPα Inhibition Clearing Tu …

CD40, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a pivotal role in regulating immune responses, particularly in activating antigen-presenting cells (APCs) and promoting T cell activation. Over the past decade, CD40 has emerged as a promising target in cancer immunotherapy due to its ability to stimulate both the innate and adaptive immune systems, driving potent anti-tumor responses. By activating CD40, researchers aim to amplify immune reactions that enhance the immune system’s ability to recognize and destroy cancer cells. This article explores the biology of CD40, its role in anti-tumor immunity, and its potential in cancer immunotherapy.What is …

B7-H3, also known as CD276, is a member of the B7 family of immune checkpoint molecules that has emerged as a compelling target in tumor immunotherapy. Initially recognized for its role in regulating immune responses, B7-H3 has gained increasing attention due to its overexpression in various cancers and its ability to promote immune evasion. As a result, B7-H3 has become a promising target for cancer immunotherapy, offering new hope for treatments aimed at improving patient outcomes by enhancing the immune system’s ability to fight tumors. AudioAssay Genie · B7-H3: A Promising New Target in Tumor ImmunotherapyWhat is B7-H3? B7-H3 is an immune regulatory molecule expres …